Cart
sales@molnova.com
Izonsteride
CAS No. 176975-26-1
Izonsteride( —— )
Catalog No. M34293 CAS No. 176975-26-1
Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 380 | In Stock |
|
| 10MG | 570 | In Stock |
|
| 25MG | 911 | In Stock |
|
| 50MG | 1190 | In Stock |
|
| 100MG | 1628 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIzonsteride
-
NoteResearch use only, not for human use.
-
Brief DescriptionIzonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.
-
DescriptionIzonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is used in the treatment of oncology and genitourinary disorders, and may be used in the study of prostate cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetReductase
-
RecptorReductase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number176975-26-1
-
Formula Weight422.61
-
Molecular FormulaC24H26N2OS2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12C=3C(=CC(SC4=NC=5C(S4)=CC=CC5CC)=CC3)CC[C@]1(N(C)C(=O)CC2)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Finasteride
Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM).
-
Ponalrestat
ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice
-
WJ-39
WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.
